Some of these issues, such as silencing β2m to inhibit HLA-class I to minimize graft rejection, and others to increase MSC efficacy, are being developed [123], as minor MHC antigen mismatched bone marrow–derived MSCs induced fibrosis in a scleroderma mouse model [124]. The gene discussed is B2M; the disease is fibrosis.